Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission

New England Journal of Medicine

Volumn 341, Issue 6, 1999, Pages 394-402

  Garcia, Patricia M ^a,i   Kalish, Leslie A ^b   Pitt, Jane ^c   Minkoff, Howard ^d   Quinn, Thomas C ^e   Burchett, Sandra K ^j   Kornegay, Janet ^f   Jackson, Brooks ^j   Moye, John ^g   Hanson, Celine ^j   Zorrilla, Carmen ^h   Lew, Judy F ^e  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NEW ENGLAND RESEARCH INSTITUTES   (United States)

^c Columbia Coll of Phys and Surgeons ^*  (United States)

^d SUNY DOWNSTATE MEDICAL CENTER   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f ROCHE MOLECULAR SYSTEMS   (United States)

^g EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^h UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

ⁱ Prentice Women's Hospital   (United States)

^j NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INFANT; MAJOR CLINICAL STUDY; MONONUCLEAR CELL; PERINATAL PERIOD; PREGNANCY; PRIORITY JOURNAL; VIRUS TRANSMISSION;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DISEASE TRANSMISSION, VERTICAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; LOGISTIC MODELS; MULTIVARIATE ANALYSIS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROSPECTIVE STUDIES; RISK FACTORS; RNA, VIRAL; TIME FACTORS; VIRAL LOAD; ZIDOVUDINE;

EID: 0033527028     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199908053410602     Document Type: Article

References (27)

1. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173-80.
2. Sheon AR, Fox HE, Rich KC, et al. The Women and Infants Transmission Study (WITS) of maternal-infant HIV transmission: study design, methods, and baseline data. J Womens Health 1996;5:69-78.
3. Cooper ER, Nugent RP, Diaz C, et al. After AIDS clinical trial 076: the changing pattern of zidovudine use during pregnancy, and the subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants. J Infect Dis 1996; 174:1207-11.
4. Rodriguez EM, Mofenson LM, Chang B-H, et al. Association of maternal drug use during pregnancy with maternal HIV culture positivity and perinatal HIV transmission. AIDS 1996;10:273-82
5. Bryson YJ, Luzuriaga K, Sullivan JL, Wara DW. Proposed definitions for in utero versus intrapartum transmission of HIV-1. N Engl J Med 1992;327:1246-7.
6. Calvelli T, Denny TN, Paxton H, Gelman R, Kagan J. Guideline for flow cytometric immunophenotyping; a report from the National Institute of Allergy and Infectious Diseases, Division of AIDS. Cytometry 1993;14: 702-15.
7. Hollinger FB, ed. ACTG virology manual for HIV laboratories: version 2.1. Bethesda, Md.: National Institutes of Allergy and Infectious Diseases, September 1993.
8. Hollinger FB, Bremer JW, Myers LE, Gold JWM, McQuay L, NIH/NIAID/DAIDS/ACTG Virology Laboratories. Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group. J Clin Microbiol 1992;30:1787-94.
9. Boom R, Sol CJ, Salimans MM, Jansen CL, Wertheim-van Dillen PM, van der Noordaa J. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990;28:495-503.
10. Shearer WT, Quinn TC, LaRussa P, et al. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. N Engl J Med 1997;336:1337-42.
11. Mantel N. Chi-square tests with one degree of freedom: extensions of the Mantel-Haenszel procedure. J Am Stat Assoc 1963;58:690-700.
12. Rosner B. Fundamentals of biostatistics. 3rd ed. Boston: PWS-Kent Publishing, 1990.
13. Hosmer DW Jr, Lemeshow S. Applied logistic regression. New York: John Wiley, 1989.
14. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126:946-54.
15. Dickover RE, Garratty EM, Herman SA, et al. Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission: effect of maternal zidovudine treatment on viral load. JAMA 1996;275:599-605.
16. Weiser B, Nachman S, Tropper P, et al. Quantitation of human immunodeficiency virus type 1 during pregnancy: relationship of viral titer to mother-to-child transmission and stability of viral load. Proc Natl Acad Sci U S A 1994;91:8037-41.
17. Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med 1996;335:1621-9.
18. Cao Y, Krogstad P, Korber BT, et al. Maternal HIV-1 viral load and vertical transmission of infection: the Ariel Project for the prevention of HIV transmission from mother to infant. Nat Med 1997;3:549-52.
19. Jackson JB, Hom D, Piwowar E, et al. Maternal HIV-1 RNA serum levels at delivery and vertical transmission in Uganda. Pediatr AIDS HIV Infect 1996;7:37-42.
20. Fang G, Burger H, Grimson R, et al. Maternal plasma human immunodeficiency virus type 1 RNA level: a determinant and projected threshold for mother-to-child transmission. Proc Natl Acad Sci U S A 1995;92: 12100-4.
21. Mayaux MJ, Dussaix E, Isopet J, et al. Maternal virus load during pregnancy and mother-to-child transmission of human immunodeficiency virus type 1: the French perinatal cohort studies. J Infect Dis 1997;175:172-5.
22. Administration of zidovudine during late pregnancy and delivery to prevent perinatal HIV transmission - Thailand, 1996-1998. MMWR Morb Mortal Wkly Rep 1998;47:151-4.
23. Fiscus SA, Adimora AA, Schoenbach VJ, et al. Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban counties. JAMA 1996;275:1483-8.
24. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. MMWR Morb Mortal Wkly Rep 1998;47(RR-2):1-30. [Errata, MMWR Morb Mortal Wkly Rep 1998;47:287, 315.]
25. Mandelbrot L, Le Chenadec J, Berrebi A, et al. Perinatal HIV-1 transmission: interaction between zidovudine prophylaxis and mode of delivery in the French Perinatal Cohort. JAMA 1998;280:55-60.
26. The European Mode of Delivery Collaboration. Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial. Lancet 1999;353:1035-9.
27. The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1: a meta-analysis of 15 prospective cohort studies. N Engl J Med 1999;340:977-87.